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Abstract
Background: The VHL protein (pVHL) is a multiadaptor protein that interacts with more than 30 different binding
partners involved in many oncogenic processes. About 70 % of clear cell renal cell carcinoma (ccRCC) have VHL
mutations with varying impact on pVHL function. Loss of pVHL function leads to the accumulation of Hypoxia
Inducible Factor (HIF), which is targeted by current targeted treatments. In contrast to nonsense and frameshift
mutations that highly likely nullify pVHL multipurpose functions, missense mutations may rather specifically
influence the binding capability of pVHL to its partners. The affected pathways may offer predictive clues to therapy
and response to treatment. In this study we focused on the VHL missense mutation pattern in ccRCC, and studied
their potential effects on pVHL protein stability and binding partners and discussed treatment options.
Methods: We sequenced VHL in 360 sporadic ccRCC FFPE samples and compared observed and expected
frequency of missense mutations in 32 different binding domains. The prediction of the impact of those mutations
on protein stability and function was assessed in silico. The response to HIF-related, anti-angiogenic treatment of 30
patients with known VHL mutation status was also investigated.
Results: We identified 254 VHL mutations (68.3 % of the cases) including 89 missense mutations (35 %). Codons
Ser65, Asn78, Ser80, Trp117 and Leu184 represented hotspots and missense mutations in Trp117 and Leu 184 were
predicted to highly destabilize pVHL. About 40 % of VHL missense mutations were predicted to cause severe protein
malfunction. The pVHL binding domains for HIF1AN, BCL2L11, HIF1/2α, RPB1, PRKCZ, aPKC-λ/ι, EEF1A1, CCT-ζ-2, and
Cullin2 were preferentially affected. These binding partners are mainly acting in transcriptional regulation, apoptosis
and ubiquitin ligation. There was no correlation between VHL mutation status and response to treatment.
Conclusions: VHL missense mutations may exert mild, moderate or strong impact on pVHL stability. Besides the HIF
binding domain, other pVHL binding sites seem to be non-randomly altered by missense mutations. In contrast to LOF
mutations that affect all the different pathways normally controlled by pVHL, missense mutations may be rather
appropriate for designing tailor-made treatment strategies for ccRCC.
Keywords: Clear cell renal cell carcinoma, VHL, Missense mutations, Binding domains, pVHL stability, Therapy
Abbreviations: ccRCC, Clear Cell Renal Cell Carcinoma; FFPE, Formalin-fixed, Paraffin-embedded; HIF,
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Background
Renal cell carcinoma (RCC) is the ninth most common
cancer type worldwide [1–3]. There are three main RCC
subtypes that are determined by their histologic features:
papillary RCC, chromophobe RCC and clear cell RCC
(ccRCC), the latter is known to be closely related with
mutation of the Von Hippel-Lindau gene (VHL). ccRCC
represents 75 % of all RCC cases and is also the most
aggressive form of this cancer type [4].
Standard treatment for localized disease is surgery
(partial or total nephrectomy), and targeted therapy as
well as novel immunotherapies for metastasizing tumors.
Despite all the recent efforts, the optimization of effi-
cient therapies remains a major challenge for most cases
of metastatic RCC [1, 5].
The VHL gene is a tumor suppressor gene of 639
coding nucleotides distributed over three exons and lo-
cated at chromosome 3p25.3 [6]. The VHL gene product
(pVHL) has been identified as a multiadaptor protein,
interacting with more than 30 different binding partners
[7]. Its best described function is to target other proteins
for ubiquitination and proteasomal degradation as com-
ponent of an E3 ubiquitin protein ligase, also termed
VBC-cul2 complex [8, 9]. Among its targets are the
hypoxia-inducible factor (HIF) subunits 1α and 2α
(HIF1α and HIF2α), which upregulate many genes, such
as VEGF, PDGF, EPO, CA9 and CXCR4, known to be
important in metastatic processes [10, 11]. In addition to
its destabilizing effect on HIF1/2α, pVHL is also in-
volved in the recruitment of many effector proteins to
regulate a variety of cellular processes including micro-
tubule stability, activation of p53, neuronal apoptosis,
cellular senescence and aneuploidy, ubiquitination of
RNA polymerase II and regulation of NFkB activity [12].
VHL has been shown to be affected in more than 80 %
of the ccRCC cases, either by allelic deletion, promoter
methylation (19 %), or mutations (70–80 %) [13, 14].
Given the multiple functions of pVHL the inactivation
of VHL is a critical point in the initiation of tumor for-
mation in the context of ccRCC [15–17].
To date, controversial data exist about correlations be-
tween VHL mutations and pathological parameters,
overall and disease-free survival [14, 18–22].
Whereas frameshift and nonsense mutations highly
likely abrogate pVHL function, the effects on pVHL
stability and binding ability of missense mutations
occurring in about 25 % of ccRCC patients are ra-
ther unclear. Such mutations may not, partly or fully
affect interacting functions of pVHL [23], which sub-
sequently influence differently biological pathways
involved in tumor carcinogenesis [24–31]. Evidence
of mutant VHL expression at the RNA level [32, 33]
as well as at the protein level [34, 35] was described
in other studies. Although pVHL mutant forms tend
to rapidly degrade, they still may exhibit partial
function [31].
We therefore hypothesize that missense mutations exert
different impact on the binding capability of pVHL targets
and its pathways which may lead to diverse tumor aggres-
siveness and response to treatment. As treatments
currently used in clinics for the metastatic disease are
mostly anti-angiogenic tyrosine-kinase inhibitors targeting
VEGFR and PDGFR to counter the upregulation of HIF
caused by inactivation of VHL, it is of considerable inter-
est to improve our knowledge on the additional HIF non-
related pathways affected by VHL mutations.
In this study, we investigated the VHL mutation status
in a cohort of 360 patients with sporadic ccRCC. We
particularly focused on missense mutations and their po-
tential biological effects on the pathways regulated by
pVHL’s interactors as well as their impact on anti-
angiogenic treatment response. The identification of
ccRCC based on the pathways potentially affected by
VHL missense mutations may be important for selecting
appropriate targeted therapies.
Methods
Patients and tissue specimens
To a previously described collection of 256 formalin-
fixed, paraffin-embedded (FFPE) tissue samples of pa-
tients with sporadic ccRCC [23], 90 additional cases
from the University Hospital of Zürich and 14 from the
Clinical Division of Oncology and Cancer Centre,
Medical University of Vienna, Austria, were reviewed by
one pathologist (H.M.). The tumors were graded accord-
ing to the classification of the World Health Organization
[4]. The median age of the patients was 64 years. Tumor
stage and Fuhrman grade of the tumors were unknown
for 14 patients. The cohort consisted of 147 (42.8 %) pT1,
31 (9 %) pT2, 160 (46.5 %) pT3 and 8 (2.3 %) pT4 ccRCC.
There were 11 (3.2 %) grade I, 105 (30.5 %) grade II, 144
(41.9 %) grade III and 86 (25 %) grade IV tumors (see also
Table 1). This study was approved by the cantonal
Table 1 Fuhrman grade, tumor stage and VHL mutation type in
346 ccRCC patients
Fuhrman n (%) Tumor stage (pT) n (%)
VHL status 1 + 2 3 + 4 1 + 2 3 + 4
Nonsense 6 (21.4) 22 (78.6) 15 (53.6) 13 (46.4)
Frame shift 43 (44.8) 53 (55.2) 51 (53.1) 45 (46.9)
Missense 21 (26.9) 57 (73.1) 45 (56.3) 35 (43.8)
In frame 6 (35.3) 11 (64.7) 6 (37.5) 10 (62.5)
Splice site 3 (20) 12 (80) 9 (56.3) 7 (43.8)
Wild-type 37 (33) 75 (67) 52 (47.3) 58 (52.7)
Tumor stage or grade information was not available for 14 patients
Combined Fuhrman grades: 1 + 2 = low grade, 3 + 4 = high grade tumors
Combined tumor stages: 1 + 2 = organ-confined, 3 + 4 =metastatic
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commission of ethics of Zurich (KEK-ZH-nos. 2011–72
and 2013–0629). Areas that contained at least 75 % tumor
cells were directly marked on the HE section of each
tumor and considered for punching.
Thirty patients were treated with at least one of the
following anti-angiogenic drugs: Sunitinib, sorafenib,
pazopanib and bevacizumab. Tumor response was evalu-
ated according to the RECIST criteria [36] and was clas-
sified into three types of response: progressive disease,
stable disease and regressive disease (partial and
complete remission) (data provided by Dr. Axel Mischo,
Department of Oncology, University Hospital Zürich).
The details of the treatments are shown in Table 3.
DNA extraction and VHL sequencing
Total DNA was extracted from 3 to 4 tissue cylinders
(diameter 0.6 mm) punched from each FFPE block and
processed following the Qiagen DNeasy Blood & Tissue
Kit (Qiagen, Germany) or the Maxwell® 16 FFPE Tissue
LEV DNA Purification Kit (Promega corporation,USA).
The first 162 base pairs of VHL are rarely mutated and
were excluded from sequence analysis [15]. The primers
used for amplification were 5’-agagtccggcccggaggaact-3’
forward, 5’-gaccgtgctatcgtccctgc-3’ reverse for exon 1,
5’-accggtgtggctctttaaca-3’ forward and 5’-tcctgtacttacca
caacaacctt-3’ reverse for exon 2, and 5’-gagaccctagtc
tgtcactgag-3’ forward and 5’-tcatcagtaccatcaaaagctga-3’
reverse for exon 3. The forward and reverse DNA se-
quences overlap and cover the VHL sequence excluding
the first 162 base pairs (Additional file 1). Sequencing was
performed as described previously [23]. The sequences
were aligned and compared to the NCBI sequence
AF010238 using the informatics tool Sequencher
(Sequencher® version 5.3 sequence analysis software,
Gene Codes Corporation, Ann Arbor, MI USA, [37]).
All VHL mutations were validated by a second inde-
pendent PCR and sequence analysis.
In silico analysis of VHL missense mutants
The effect of missense mutation on the stability of pVHL
and its potential association to the disease were pre-
dicted in silico using the program Site Directed Mutator
(SDM) [38]. The crystal structure of pVHL was isolated
from VCB complex 1 lm8.pdb crystal structure (Piccolo
database) and uploaded into the program to calculate
the thermodynamic change (ddG) occurring after modi-
fication of one amino acid according to the main chain
conformation, solvent accessibility and hydrogen bond-
ing class. The missense mutations were then classified as
follows:
– ddG < −2.0: highly destabilizing and disease-
associated
– −2.0 ≤ ddG < − 1.0: destabilizing
– −1.0 ≤ ddG < −0.5: slightly destabilizing
– −0.5 ≤ ddG ≤ 0.5: neutral
– 0.5 < ddG ≤ 1: slightly stabilizing
– 1.0 < ddG ≤ 2: stabilizing
– ddG > 2.0: highly stabilizing and disease-associated
The mapping of pVHL’s interactors binding domains
has been adapted from Leonardi et al. [7].
Statistics
A two-tailed Chi-Square statistics test with one degree
of freedom was used for all the statistical tests in this
study. Preferentially mutated codons of VHL were deter-
mined by calculating observed and expected frequencies
of 88 out of 89 missense mutations.
Results
VHL mutation types, mutation sites, tumor stage and
grade distribution
Two hundred forty-six of 360 (68.3 %) sequenced ccRCC
were mutated. Eight of these tumors had two mutations.
The frequencies of the VHL mutation types are illus-
trated in Fig. 1.
Since deletions, insertions, splice site mutations and
nonsense mutations most likely abrogate most if not all
pVHL functions, they were referred to as loss of func-
tion (LOF) mutations. An overview of VHL LOF and
missense mutation sites in the pVHL sequence and the
affected binding domains of pVHL’s interactors are
shown in Fig. 2.
VHL mutation frequencies were similar in organ-
confined pT1/2 and metastasizing pT3/4 ccRCC. There
was no correlation between the number of mutations and
stage or grade (Table 1). Additional information of the
ccRCC specimens and the 256 mutations is given in
Additional file 2: Table S1 and Additional file 3: Table S2.
VHL mutation hotspots
A closer look at the mutation sites within the protein re-
vealed that some codons were more frequently mutated
than others. Fourteen mutations (5.5 %) were located at
Ser65, nine (3.5 %) at Trp117, 8 (3.1 %) at Phe76, 7
(2.8 % each) at Asn78, Ser80, Leu135, and Arg161, 6
(2.4 %) at His115, and 5 mutations were at Gly114 and
Leu184 (2 % each).
The codons that were most often affected by missense
mutations were Ser65, Asn78, Ser80 (six mutations each,
6.7 %), Trp117 and Leu184 (five mutations each, 5.6 %).
Codons Phe76 and Leu135 showed only LOF mutations.
Preferentially affected binding domains of pVHL
interactors
We next assigned 88 of 89 missense mutations to the
putative binding domains of 32 pVHL interactors. One
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missense mutation in the stop codon was excluded from
this analysis. As expected, large binding domains of
interacting partners covering more than 60 amino acids
of pVHL showed relative high frequencies of mutations.
Between 44 and 100 % of the missense mutations were
located in the VHLAK (100 %), HIF1AN (77.3 %),
BCL2L11 (70.5 %), RPB1 (60.2 %), and RPB7 (44.3 %)
binding domains. Notably, about half of the missense
mutations (45/88, 51.1 %) resided in the HIF1α and
HIF2α (EPAS1) binding domain comprising 51 amino
acids.
Between 20 and 35 % of the missense mutations were
located in the binding domains of PRKCD, VDU1/2,
PRKCZ, EEF1A1, Nur77 and CARD9 (25–60 amino
acids). The frequencies of missense mutations found in
the smaller binding domains (9–28 amino acids) of
JADE1, SP1, KIF3A, TUBA4A, HuR, aPKC-λ/ι, TBP1,
CCT-ζ-2, EloC and p53 ranged between 8 and 23 %. All
interactors, related pathways and binding domains af-
fected by mutations are listed in Table 2.
Missense mutations which preferentially affected bind-
ing domains were identified by comparing the observed
number with the expected number of mutation and by
normalizing for each binding domain based on their
amino acid length. As the first 54 amino acids of pVHL
were not covered by Sanger sequencing, the expected
number of missense mutation per codon was 0.55. We
found that the binding domains showing significantly
higher rates of missense mutations were for pVHL
interactors HIF1AN, BCL2L11, HIF1α, HIF2α, RPB1,
PRKCZ, aPKC-λ/ι, EEF1A1, CCT-ζ-2, and Cullin2. pVHL
binding partners with involved pathways and the ratio of
observed versus expected frequency of missense muta-
tions are shown in Table 2. Additional information on
pVHL binding partners is given in Additional file 4.
VHL missense mutations and pVHL stability
Eighty-eight missense mutations were analyzed in silico
using the program SDM to determine the protein
thermodynamic change (ddG) triggered by those muta-
tions. In this context, ddG is an indicator of pVHL sta-
bility and suggests whether or not a missense mutation
causes deleterious functional impact and is associated
with disease.
A large proportion of the VHL missense mutations
(60/88, 68 %) were predicted to destabilize the resulting
360 cases
246 tumors mutated 
(68.3%)
254 mutations (8 
double)
116
deletions/insertions 
(45.7%)
99 frameshift (85.3%)
17 in frame (14.7%)
18 splice site 
mutations (7.1%)
120 point mutations 
(47.2%)
1 silent mutation
30 nonsense 
mutations (25%)
89 missense mutations 
(75%)
114 wild-type (31.7%)
Fig. 1 VHL sequence analysis of 360 ccRCC with frequencies of mutated tumors, total number of VHL mutations (including double mutations) as
well as VHL mutation types. Deletions/Insertions were grouped into frameshift and in frame mutations; Point mutations were grouped into silent,
nonsense and missense mutations
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protein (ddG < −0.5), eleven mutations (11/88, 12.5 %)
had a neutral effect (−0.5 < ddG < 0.5), and 17 had a sta-
bilizing effect (17/88, 19.3 %) on pVHL. Thirty-three of
88 (37.5 %) missense mutations were highly destabilizing
and only 2 (2.3 %), were highly stabilizing, suggesting
that about 40 % of VHL missense mutations were
predicted to cause protein malfunction (ddG < −2 and
ddG > 2 respectively). VHL missense mutations and their
predicted effects on pVHL stability and association with
disease are listed in Additional file 5: Table S3.
By focusing on the HIF1/2α binding domain (amino
acids 67–117) and the remaining parts of the protein
(amino acids 54–66, 118–213) we observed signifi-
cantly more missense mutations in the HIF1/2α bind-
ing domain than expected (43/88 observed, 28/88
expected (p-value <0.0001). However, the frequency of
destabilizing mutations (ddG < −0.5) in the HIF1/2α
binding domain (32/45, 71.1 %) was similar to that
seen for the remaining parts of the protein (28/43,
65.1 %).
Notably, all of the hotspot missense mutations found
in codons Trp117 and Leu184 were destabilizing and 3
out of 5 and 5 out of 5 mutations, respectively, were
predicted to cause protein malfunction. In addition, all
missense mutations in codon Ser80 destabilize pVHL,
codon Ser65 had 3 destabilizing and 3 stabilizing mu-
tations, and codon Ser65 had 2 destabilizing and 4
stabilizing mutations. The sites of all missense muta-
tions are shown together with their stability predic-
tion in Fig. 3.
pVHL mutations and treatment response
After surgical resection of the primary tumor, 30 pa-
tients from the cohort were treated with anti-angiogenic
Fig. 2 Frequencies of VHL LOF (loss of function; blue) and missense mutations (cyan), mutation sites and affected binding domains of pVHL’s
interactors. Note: the first 162 base pairs (54 amino acids) were not sequenced
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drugs that are currently used in clinics for patients with
metastatic ccRCC. These patients were subdivided into
three groups according to response to therapy: progres-
sive, stable and regressive disease. Treatment adminis-
tered, response, VHL mutation status, tumor stage and
grade are listed in Table 3.
The proportion of responders (stable + regressive disease)
was 52.6 % for the LOF (10/19), 33.3 % for the missense
mutations (2/6), and 40 % for the wild-type VHL (2/5).
There was no correlation between disease progression
status, tumor stage, grade, VHL mutation types and spe-
cific treatments.
Table 2 List of interactors and binding domains, number of missense mutations, comparison observed/expected frequency, and
pathway affected
Name of the
interactor
pVHL AA
involved
Missense mutations
count N (%)
Frequency of observed missense
mutations compared to expected
p-value Pathway of the interactor
CK2 S33, S38, S43 0 (0) lower ns Protein amino acid phosphorylation
GSK3 S68 1 (1.1) 1.8X higher ns Wnt signaling pathway
CK1 S72 1 (1.1) 1.8X higher ns Wnt signaling pathway
NEDD8 K159 1 (1.1) 1.8X higher ns Ubl conjugation pathway
KIFAP3 1–54 0 (0) lower ns Microtubule-based movement
HIF1αN 1–155 68 (77.3) 1.2X higher ** HIF1α pathway
VDU1/USP33 54–83 22 (25) 1.3X higher ns Ubl conjugation pathway
VDU2/USP20 54–83 22 (25) 1.3X higher ns Ubl conjugation pathway
RPB7 54–113 39 (44.3) 1.2X higher ns Regulatory RNA pathways
VHLAK 54–213 88 (100) equal not applicable Apoptosis
BCL2L11 55–143 62 (70.5) 1.3X higher ** Apoptosis
HIF1α 67–117 45 (51.1) 1.6X higher *** Hif1_tf pathway
EPAS1 (HIF2α) 67–117 45 (51.1) 1.6X higher *** Vegfr1_2 pathway
RPB1 60–120 53 (60.2) 1.6X higher *** Regulatory RNA pathways
PRKCZ 87–122 30 (34.1) 1.5X higher ** Antiapoptosis, intracellular Signaling
CARD9 92–121 22 (25) 1.3X higher ns NFKB and MAPK signalling
TUBA4A 95–123 20 (22.7) 1.3X higher ns MT stabilization and dynamic cell
polarity
KIF3A 95–123 20 (22.7) 1.3X higher ns Hedgehog_gli pathway
SP1 96–122 20 (22.7) 1.3X higher ns TGF-beta signaling pathway
JADE1 96–122 20 (22.7) 1.3X higher ns Apoptosis
PRKCD 113–122, 130–154 26 (29.5) 1.4X higher ns Regulation of receptor activity,
senescence
aPKC-λ/ι 114–122 16 (18.2) 3.2X higher *** Signalling by NGF
EEF1α1 114–138 23 (26.1) 1.7X higher ** Protein biosynthesis
CCT-ζ-2 116–119, 148–155 13 (14.8) 2X higher ** Chaperone-mediated protein
complex assembly
TBP1 136–154 7 (8) 1.5X lower ns Signaling by Wnt, DNA Replication,
Apoptosis
p53 154–163 8 (9.1) 1.5X higher ns Apoptosis
Nur77 155–213 20 (22.7) 1.6X lower ** MAPK and NGF signaling pathways
EloC 157–171 11 (12.5) 1.3X higher ns Ubl conjugation pathway
HuR (RNA binding
protein)
157–184 19 (21.6) 1.2X higher ns mRNA stabilization
EloB 170–174 1 (1.1) 2.8X lower ns Ubl conjugation pathway
Cullin2 181–184 6 (6.8) 2.7X higher ** Ubl conjugation pathway
VBP1 187–213 1 (1.1) 14.9X lower *** Morphogenesis
14 splice site mutations and a frameshift mutation for which the position of the affected amino acid cannot be determined and the missense mutation c.642 A >
C/ p.X214Cys are excluded from this table. p-value summary: P-value: * < 0.05, ** < 0.01, *** < 0.001, ns “not significant”
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Discussion
It is widely accepted that in almost all ccRCC both VHL
alleles are inactivated by chromosome 3p loss, mutation
and hypermethylation [13, 14, 39]. In contrast to frame-
shifts, nonsense codons and alteration of splice sites,
which highly likely cause loss of function of pVHL in
about 50 % of these tumors, the consequences of VHL
missense mutations present in 25 % may significantly
vary. A detailed and comprehensive investigation of such
mutations in this context can hardly be found in the lit-
erature. The goal of our study was therefore to sequence
the VHL tumor suppressor gene in 360 ccRCC patients
and characterize missense mutations by focusing on
preferentially affected sites in the gene and their poten-
tial consequences on pVHL function and its binding
partners.
Intratumoral heterogeneity is a common feature of
most cancers and represents a big challenge for molecu-
lar diagnostics. To avoid any false negative artifacts we
paid attention to analyze the VHL sequence of one par-
affin embedded ccRCC tissue block that contained at
least 70 % tumor cells. The high mutation rate in our
ccRCC cohort confirmed previous results showing that
VHL alteration is rather independent of heterogeneity
and ubiquitously present in ccRCC [40]. In cases with
intratumoral heterogeneity related to VHL, own studies
have shown the presence of de novo VHL mutations
[41]. Minor populations of tumor cells with VHL muta-
tions are extremely rare [40]. We therefore conclude
that most non-mutated tumors were in fact VHL wild
type and that the use of more than one FFPE block to
analyze one tumor would have not influenced signifi-
cantly our results. Next generation sequence analysis of
additional genes demonstrated that intratumoral hetero-
geneity increases with the number of tumor regions se-
quenced [40, 42]. The relevance of molecular findings in
other genes may thus be more reliable if several blocks
are used. The analysis of several areas in one tumor
could allow identifying subclonal driver mutations in
other genes that may be responsible for drug resistance.
The frequency of VHL mutations found in about 70 %
of the patients was comparable to previously published
data [16]. There was no correlation with VHL mutation
types and the prognostic parameters tumor stage and
grade, which is consistent with previous studies [16,
20, 43]. Although most of the VHL mutations were
private, we found several hotspot mutations in our
cohort. Between 5 and 14 mutations affected codons
Ser65, Phe76, Asn78, Ser80, Gly114, His115, Trp117,
Leu135, Arg161 and Leu184. Interestingly, approxi-
mately one third of the 88 missense mutations oc-
curred at codons Ser65, Asn78, Ser80, Trp117 and
Leu184 (5–6 mutations per codon). Those missense
mutations have already been described in the VHL
mutations database-UMD [44] and in the COSMIC
database for ccRCC [45] where they represent about
10 % of all VHL mutations. This frequency is consist-
ent with our finding (28/256, 10.9 %) and confirms
the quality of the sequencing data obtained from our
patient cohort.
In addition to the hotspot missense mutations, we
also noticed considerable discrepancies between the
expected and observed number of missense mutations
which particularly affected the binding domains of 10
of 32 pVHL targets. Significant more missense muta-
tions than expected were seen in binding domains
specific for HIF1AN, BCL2L11, HIF1α, HIF2α, RPB1,
PRKCZ, aPKC-λ/ι, EEF1A1, CCT-ζ-2, and Cullin2.
Apart from HIFα, most of these proteins are mainly
involved in apoptosis (BCL2L11, aPKC-λ/ι), transcrip-
tional regulation (RPB1, PRKCZ) and ubiquitin
ligation (CCT-ζ-2, Cullin2). Some of these missense
mutations may exert pleiotropic effects on different
pathways. This was recently shown with the mutants
Phe81Ser and Arg167Gln which cause partial abrogation
of VBC complex interactions and fail to downregulate
HIF1/2α. Simultaneously, they also lead to enhanced anti-
apoptosis signaling and weaken the assembly of RNA
Polymerase II complex and protein ubiquitination signal-
ing pathway [46]. Notably, the binding sites for aPKC-λ/ι,
CCT-ζ-2, and Cullin2 were the most affected ones and
may thus represent potential drug targets alternatively to
HIF. For example, disruption of pVHL binding leads to
subsequent ubiquitination of aPKC-λ/ι, which in turn de-
regulates JunB expression and promotes tumor progression
Fig. 3 Distribution and frequency of VHL missense mutations and
their predicted effects on pVHL stability using the program Site
Directed Mutator (SDM) [38]
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Table 3 Treatment, response, and VHL mutation status of the patients treated with anti-angiogenic therapies
Mutation Mutation
consequence
Functionality
prediction
Interacting partners Disease progression
status
Treatment pT
stage
Fuhrman
grade
c.163delG/
p.Glu55ArgfsX11
fs LOF PD Pazopanib > Everolimus 3 3
c172delC/
p.Arg58GlyfsX9
fs LOF PD IFNa > Pazopanib
c.194C > T/p.Ser65Leu missense stabilizing HIF1αN/VDU1/USP33/
VDU2/USP20/RPB7/
VHLAK/BCL2L11/RPB1
PD Sunitinib
c.240 T > A/p.Ser80Arg missense destabilizing HIF1αN/VDU1/USP33/
VDU2/USP20/RPB7/
VHLAK/BCL2L11/
HIF1α/EPAS1/RPB1
PD IFNa > Sorafenib 1
c. 262 T > A/p.Trp88Arg missense highly
destabilizing
HIF1αN/RPB7/VHLAK/
BCL2L11/HIF1α/
EPAS1/RPB1/PRKCZ
PD Sunitinib 3 3
c.268_273del/
p.Asn90_Phe91del
in frame LOF PD Sunitinib 3
c.IVS1 + 1G > A
(c.340 + 1G > A)
splice mut LOF PD Sorafenib > Sunitinib >
Everolimus
c.345_364del/
p.Leu116ArgfsX9
fs LOF PD IFNa > Sorafenib
c.349delT/
p.Trp117GlyfsX42
fs LOF PD Sunitinib 3 3
c.484 T > C/p.Cys162Arg missense neutral VHLAK/p53/Nur77/
EloC/HuR
PD Sunitinib > Sorafenib >
Everolimus > Pazopanib
3 3
c.497_505del9/
p.Arg167ValdelSerLeu
in frame LOF PD Sunitinib 3 3
C.580_583delinsAA/
p.Val194LysfsX61
fs LOF PD Sunitinib > Sorafenib
c.586A > T/p.Lys196X nonsense LOF PD Sunitinib > Sorafenib >
Everolimus
1
wild-type wild-type PD Pazopanib 3 4
wild-type wild-type PD Sunitinib > Pazopanib >
Sorafenib > Everolimus
4 3
wild-type wild-type PD Sunitinib 2 3
c.161_162delTG/
p.Met54ArgfsX77
fs LOF SD Sunitinib 3 4
c.203C > A/p.Ser68X nonsense LOF SD Sorafenib > Pazopanib >
Everolimus
3 4
c.327insA/
p.His110ProfsX22
fs LOF SD Sunitinib > Sorafenib 1 4
c.IVS1 + 2 T > A
(c.340 + 2 T > A)
splice mut LOF SD Pazopanib > Axitinib 3 3
c.345insC/
p.Leu116ProfsX15
fs LOF SD Bevacizumab > IFNa >
Pazopanib
3 4
c.350delG/
p.Trp117CysfsX42
fs LOF SD IFNa/Bevacizumab 1 3
c.481C > T/p.Arg161X nonsense LOF SD Sorafenib 2 2
wild-type wild-type SD Sunitinib > Sorafenib >
Everolimus
c.167_168delCC/
p.Ala56GlyfsX75
fs LOF RD Sorafenib 3 1
c.227_229del3/
p.Phe76del
in frame LOF RD Pazopanib > Sunitinib 1 3
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in VHL disease-related pheochromocytoma. Uncontrolled
expression of JunB may also be important in ccRCC as
JunB was found to be upregulated in sporadic, pVHL inac-
tivated, ccRCC [47, 48]. Moreover, VHL mutations were
shown to impair the interaction with pVHL and CCT-ζ-2
which, consequently, caused improper folding of the VBC
complex [25, 49]. Given the function of Cullin2 a default in
VBC complex formation may also be expected from dis-
rupted binding of pVHL with this protein. Interestingly, the
binding domain for VBP1 located at the 3’ end of VHL
exon 3 seems to be spared from mutations. VBP1 functions
as a chaperone protein and may play a role in the transport
of pVHL from the perinuclear granules to the nucleus or
cytoplasm [50]. The strikingly low frequency of mutations
(15 times lower than expected) in this region of VHL may
reflect the importance of sustaining accurate pVHL traffick-
ing in ccRCC. This is supported by a previous report show-
ing that ccRCC with pVHL expression in both nuclear and
cytoplasmic compartments had a better prognosis [34].
The effects of missense mutations on protein stability
were determined in silico by calculating the thermo-
dynamic change caused by one missense mutation. The
tool for determining protein stability was proven powerful
with mutations predicted to be highly destabilizing leading
to both faster degradation of pVHL and stabilization of
HIF1/2α [23]. Based on this observation it is conceivable
that those mutations are critical for most if not all binding
partners of pVHL.
In addition to their potential influence on pVHL func-
tion we also attempted to further characterize the 88
missense mutations with regard to their tumorigenic po-
tential. We used the Symphony classification system that
allows subclassifying VHL missense mutations in VHL
disease patients according to their risk of developing
ccRCC [51]. Among the 88 missense mutations, 61
(80 %) were classified by Symphony as high risk of de-
veloping ccRCC. We conclude that most of the missense
mutations, even those with neutral or mild impact on
pVHL stability as predicted by SDM, may have strong
tumorigenic potential. Notably, only two of the remaining
17 missense mutations were highly destabilizing muta-
tions (Ile151Ser and His115Leu) and classified as low risk
of ccRCC.
Current therapeutic strategies for ccRCC focus on
Tyrosine Kinase Inhibitors (such as sunitinib, sorafenib,
pazopanib, axitinib) or other anti-angiogenic drugs (i.e.
bevacizumab) to counteract VEGF/ PDGF upregulation
in VHL mutated tumors with accumulated HIF1/2α [52].
Treatment with Sunitinib as the most commonly used
targeted therapy show mainly partial response in 31 % of
the patients with metastatic ccRCC [5]. It is tempting to
speculate that the response rate of ccRCC patients may
be linked to the VHL mutation type present in a tumor.
We therefore analyzed follow-up data of 30 ccRCC pa-
tients with known VHL mutation status who were
treated with anti-angiogenic drugs. Fifty-three percent of
the patients with LOF, 33 % with missense mutations,
and 40 % wild-type responded to the treatment (regres-
sive or stable disease). No significant association was
seen between VHL mutation status and response to
treatment in our cohort, although a higher response rate
in patients with LOF compared to wild-type or missense
mutations has been described in a larger study [22].
Using novel high throughput sequencing platforms
novel driver genes were identified in ccRCC. Frequent
alterations were found in the genes SETD2, BAP1, and
PBRM1, which are all located on chromosome 3p in close
proximity to VHL [53]. Mutations in the two latter genes
seem to be linked to enhanced cell proliferation, tumor
aggressiveness and patient outcome. Twenty percent of
ccRCC have mutations in MTOR, TSC1, PIK3CA, and
PTEN and indicates that deregulated mTOR pathways
may also be critical in this tumor subtype. Interestingly,
up to 5 % of ccRCC with intact VHL are characterized by
loss of heterozygosity of 8q21 and mutations in TCEB1,
which is located in this chromosomal region. TCEB1 en-
codes Elongin C, a member of E3 ubiquitin protein ligase
that binds to pVHL. The new 2016 WHO classification
Table 3 Treatment, response, and VHL mutation status of the patients treated with anti-angiogenic therapies (Continued)
c.340G > T/p.Gly114Cys missense neutral HIF1αN/VHLAK/BCL2L11/
HIF1α/EPAS1/RPB1/
PRKCZ/CARD9/TUBA4A/
KIF3A/SP1/JADE1/
PRKCD/aPKC-λ/ι/
EEF1A1
RD IFNa > Bevacizumab 2 3
c.383 T > C/p.Leu128Proa missense higly
destabilizing
HIF1αN/VHLAK/BCL2L11/
EEF1A1
RD Pazopanib 3 4
c.430G > T/p.Gly144Xa nonsense LOF RD Pazopanib 3 4
c.458 T > C/p.Leu153Pro missense destabilizing HIF1αN/VHLAK/PRKCD/
CCT-ζ-2/TBP1
RD Sunitinib 2 3
wild-type wild-type RD Pazopanib > Everolimus 3 3
PD progressive disease, SD Stable disease, RD Regressive disease, LOF loss-of-function, fs frameshift
aone patient with two mutations
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has not yet recognized RCC with TCEB1 mutations as
own tumor entity, but included such tumors in the cat-
egory of emerging entities [54, 55]. A future RCC termin-
ology could be based even more on such molecular
findings. In ccRCC, loss of function of either pVHL or
Elongin C may result in HIF stabilization. In search for
better individualized therapies of ccRCC, these discoveries
suggest the need to open a new consensus on terminology,
cut-offs and genetic classification when dealing with the
analytical and interpretative phases of molecular findings.
Fig. 4 Impact of VHL mutation type on pVHL function and possible treatment strategies
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Conclusions
In summary, our VHL sequence analysis of 360 ccRCC
revealed pVHL binding sites which are preferentially
altered by missense mutations. In contrast to LOF
mutations which probably influence most of the pVHL
regulated pathways, missense mutations may rather de-
regulate only single or few of those pathways. Moreover,
about 15 % of ccRCC patients having missense muta-
tions with no, mild or only moderate impact on pVHL
function even may have fully or at least partially func-
tional pVHL. As a consequence, pVHL may retain full
ability to degrade HIF1/2α but lose its binding ability
to other interactors and vice versa. We therefore
hypothesize that the relatively low response rate to
anti-angiogenic drugs may be explained by the multi-
purpose nature of pVHL and the manifold effects on
pathways caused by the different mutation types. Pa-
tients with VHL missense mutation may rather benefit
from targeted therapies than patients with LOF mutations
(Fig. 4). For VHL wild-type tumors, other therapy modal-
ities aiming at pVHL non-related pathways controlled by
tumor suppressors such as PBRM1, SETD2 or BAP1 may
be more appropriate than the common anti-angiogenic
treatment [56–64].
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